Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial

The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.

Authors

Institutions

Publication Details

Journal
European Journal of Cancer
Published
2025-11-22
DOI
https://doi.org/10.1016/j.ejca.2025.116133
Citations
1
Primary Topic
Colorectal Cancer Treatments and Studies
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial

Markus Moehler, Alexander Kiani, Sebastian Stintzing, Thomas Decker et al.
1 citations
European Journal of Cancer
Colorectal Cancer Treatments and Studies
1.05
article

Impact of sex on efficacy and safety of 1st-line treatment with FOLFIRI plus cetuximab or bevacizumab in RAS/BRAF wildtype metastatic colorectal cancer – A subgroup analysis of the FIRE-3 (AIO KRK-0306) trial

Markus Moehler, Alexander Kiani, Sebastian Stintzing, Thomas Decker, Julian Walter Holch, Andreas Werner Jung, Dominik Paul Modest, Christoph Lerchenmüller, Swantje Held, Kathrin Heinrich, Christoph Kahl, Salah‐Eddin Al‐Batran, Tobias Heintges, Florian Kaiser, Ludwig Fischer von Weikersthal, Werner Scheithauer, G. Seipelt, Frank Kullmann, Volker Heinemann
article en
1 citations

Abstract

The exploratory analysis of FIRE-3 suggests that the efficacy of cetuximab combined with FOLFIRI in RAS wild-type mCRC is related to sex and primary tumor sidedness. The results support the inclusion of patient sex into the design of future trials.

European Journal of CancerVol. 232
Goethe University Frankfurt (DE), German Cancer Research Center (DE), Johannes Gutenberg University Mainz (DE), University of Applied Sciences Landshut (DE), Heidelberg University (DE), Bayreuth Medical Center (DE), LMU Klinikum (DE), Comprehensive Cancer Center Vienna (AT), Ravensburg University of Cooperative Education (DE), German Cancer Society (DE), Klinikum Magdeburg (DE), Klinikum Weiden (DE), Institute of Clinical Cancer Research (DE), AIO Studien gGmbH (DE), University Hospital Frankfurt (DE), Krankenhaus Nordwest (DE), Lukaskrankenhaus (DE), Comprehensive Cancer Center Erlangen (DE), Klinikum St. Marien Amberg (DE), Medical University of Vienna (AT), Ludwig-Maximilians-Universität München (DE)
Openalex Percentile: Top 16%
Colorectal Cancer Treatments and Studies
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.